Featured Research

from universities, journals, and other organizations

Role For Gefitinib In Asian Nonsmokers With Lung Cancer Established

Date:
September 16, 2008
Source:
European Society for Medical Oncology
Summary:
The targeted therapy gefitinib should be considered a first-line therapy for nonsmoking Asian patients with adenocarcinoma of the lung, one of the most common types of lung cancer, suggests a presentation at the 33rd Congress of the European Society for Medical Oncology.

The targeted therapy gefitinib should be considered a first-line therapy for non-smoking Asian patients with adenocarcinoma of the lung, one of the most common types of lung cancer, suggests a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

Asia has a high proportion of lung cancer patients who are non-smokers, a significant proportion of whom develop a form of cancer known as adenocarcinoma.

"Around 50% to 60% of this population have tumors with mutations in the epidermal growth factor receptor, and we know that patients with such mutations have a significantly better treatment outcome with gefitinib," said researcher Prof. Tony Mok from the Chinese University of Hong Kong.

"Currently, gefitinib and other EGFR tyrosine kinase inhibitors are considered as second line therapy for advanced non-small-cell lung cancers, meaning that the drugs should only be used after cancers fail to respond to the standard cytotoxic chemotherapy."

Prof. Mok's group studied 1,217 lung cancer patients who had never received chemotherapy and had never smoked or were light ex-smokers. Half the group was treated with gefitinib 250 mg/day or a combination of carboplatin and paclitaxel.

Over 22 months of follow-up, the researchers found that gefitinib was more tolerable and resulted in a greater likelihood of response.

"We have demonstrated better treatment outcomes with gefitinib over standard chemotherapy as first-line therapy for this clinically selected population," Prof. Mok said. "Our study has established the role of gefitinib as one of the standard first-line therapies for a clinically selected group of non-/light smokers with adenocarcinoma."


Story Source:

The above story is based on materials provided by European Society for Medical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology. "Role For Gefitinib In Asian Nonsmokers With Lung Cancer Established." ScienceDaily. ScienceDaily, 16 September 2008. <www.sciencedaily.com/releases/2008/09/080915121327.htm>.
European Society for Medical Oncology. (2008, September 16). Role For Gefitinib In Asian Nonsmokers With Lung Cancer Established. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2008/09/080915121327.htm
European Society for Medical Oncology. "Role For Gefitinib In Asian Nonsmokers With Lung Cancer Established." ScienceDaily. www.sciencedaily.com/releases/2008/09/080915121327.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins